FDA Approved: KANJINTI — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for KANJINTI (trastuzumab-anns) submitted by Amgen, Inc. The action represents a regulatory approval related to a supple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• KANJINTI (TRASTUZUMAB-ANNS)

Snippet

SUPPL AP for KANJINTI (TRASTUZUMAB-ANNS)